Vir Biotechnology says FDA grants Fast Track status to prostate cancer drug VIR-5500
Bitget2026/10/08 12:39Vir Biotechnology’s VIR-5500 won FDA Fast Track designation for late-line metastatic castration-resistant prostate cancer. Program is co-developed with Astellas under a global collaboration. Vir expects to start pivotal Phase 3 trials in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065408), on October 08, 2026, and is solely responsible for the information contained therein.
- Vir Biotechnology’s VIR-5500 won FDA Fast Track designation for late-line metastatic castration-resistant prostate cancer.
- Program is co-developed with Astellas under a global collaboration.
- Vir expects to start pivotal Phase 3 trials in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
